VALID
发表于 2025-3-23 13:41:52
,Substance P–Saporin for the Treatment of Intractable Pain,ly links a biological toxin (SAP) and an endogenous peptide (SP) that targets that toxin to the subset of neurons expressing the NK1 receptor. SP-SAP, currently in phase I clinical trials, is unique as the only targeted toxin for pain to undergo human testing. We review the history of SP-SAP and rel
champaign
发表于 2025-3-23 13:51:27
Recombinant Immunotoxins for Chronic Inflammatory Disease,c inflammatory disorders like atopic dermatitis, rheumatoid arthritis, and diabetic ulcers, as many of these are strongly age related. There is thus an increasing demand to develop better therapeutic strategies to manage and cure chronic diseases. In many of these diseases, the trigger for onset of
骑师
发表于 2025-3-23 18:42:37
BL22: A Milestone in Targeting CD22,xotoxin. The antibody fragment that binds to the target cell is internalized along with the toxin, and the toxin fragment is transported to the cytosol where it catalytically kills the cell. Preclinical development showed significant cytotoxicity and antitumor activity toward CD22+ leukemia and lymp
人充满活力
发表于 2025-3-23 23:04:29
http://reply.papertrans.cn/67/6662/666181/666181_14.png
BAN
发表于 2025-3-24 04:09:25
http://reply.papertrans.cn/67/6662/666181/666181_15.png
行业
发表于 2025-3-24 08:04:47
http://reply.papertrans.cn/67/6662/666181/666181_16.png
BUCK
发表于 2025-3-24 11:12:25
http://reply.papertrans.cn/67/6662/666181/666181_17.png
Muscularis
发表于 2025-3-24 16:03:39
2296-6056 will be of interest to biotech companies and researchers working in the fields of immunology, pharmacology, and oncology..978-3-319-83609-6978-3-319-46877-8Series ISSN 2296-6056 Series E-ISSN 2296-6064
FECK
发表于 2025-3-24 20:28:23
http://reply.papertrans.cn/67/6662/666181/666181_19.png
雪白
发表于 2025-3-25 00:24:16
http://reply.papertrans.cn/67/6662/666181/666181_20.png